Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

At Week-104 of the BRAVE-AA2 trial, this study found that 90.2% of severe alopecia areata patients who continued on baricitinib 4mg maintained hair regrowth, whereas 45.2% of those who reduced their dosage to 2mg experienced a loss of treatment benefit.

This study reports the first identification of the deleterious NIPAL 4 variant, associated with autosomal recessive congenital ichthyosis, in an American Bully and describes its clinical management and follow-up.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

Using mouse hair follicle organoids, this study demonstrated that BMP4 plays a key role in controlling hair follicle coloration and growth, as well as directing Nestin-positive stem cells towards becoming melanocytes, the pigment-producing cells responsible for hair color.

In this study, conditional deletion of BRD4 in OX40-expressing cells of mice led to alopecia, dermatitis, and loss of hair follicle stem cell function, revealing BRD4's role in skin inflammation and stem cell regulation.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This study reports that PADI4, an enzyme involved in posttranslational protein modifications, regulates progenitor cell transitions in hair follicle development by repressing transcription and interacting with translational and ribosomal processes.

This study used a novel fluorescent tagging method in mice to observe collagen IV dynamics during hair follicle development, revealing that alterations in basement membrane turnover can influence epithelial progenitor cell behavior and organ morphology by affecting cell proliferation and movement.

This study reported the first case of a NIPAL4 c.527C>A mutation in Romanian patients with autosomal recessive congenital ichthyosis, finding that NIPAL4 mutations are more common than TGM1 mutations in this population.

This study suggests that BTP levels in cerebrospinal fluid might help diagnose CIDP and predict therapy response but require validation in larger cohorts.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

This study reported that specific inhibition of the classical complement pathway with BIVV009 prevented C3 deposition along the dermal-epidermal junction in bullous pemphigoid, reflecting its potential efficacy.

This study found that 4-(4-Phenoxybenzoyl)benzoic acid derivatives may act as antioxidants by scavenging certain reactive oxygen species but exhibit prooxidant behavior under specific conditions.

This study found that individuals with alopecia areata had significantly higher serum levels of retinol-binding protein 4 and increased IgG immunoreactivity against it, suggesting a role in the disease's pathogenesis.

This study found that serum FABP4 levels were significantly higher in alopecia areata patients compared to healthy controls and may correlate with disease severity.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This study found that adults with atopic dermatitis who were treated with baricitinib at doses of 2mg or 4mg experienced significant improvements in work productivity, potentially leading to substantial indirect cost savings for employers over 16 weeks.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

This study found significant upregulation of IDO-1 and IDO-2 in human basal cell carcinomas, suggesting that IDO production may confer immune privilege characteristics to the tumors, potentially impacting their growth.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

In this study, deletion of ROBO4 in mice ameliorated hair loss caused by elevated PAF levels, suggesting potential interplay with VLDLR-related pathways.

In a randomized controlled trial, King et al. found that oral baricitinib at doses of 2 mg and 4 mg significantly improved hair regrowth in adults with alopecia areata compared to placebo, supporting its efficacy and safety for those with substantial scalp hair loss.

This study investigated the histogenetic relationship between basal cell carcinoma and hair follicles, revealing specific staining patterns of a monoclonal antibody in different skin tissues.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.